Reported 1 day ago
Investors are looking towards Alzheimer's treatments as a potential market similar to the obesity sector, with major companies like Biogen and Eli Lilly making significant investments. Key drugs like Leqembi and Kisunla are already approved, but their impact and market potential depend on ongoing trials and regulatory approvals. Analysts predict that success in these areas could significantly enhance share prices, with potential market revenue reaching $13 billion by 2030.
Source: YAHOO